Evidence map›Paper›PMID 29149366›Full record

ArticleEuropean journal of clinical pharmacology2018

Prescribing of NOACs has outnumbered warfarin: exploring how physicians choose anticoagulant treatments.

Anne Katrine Eek, Erik Øie, Anne Gerd Granas

Abstract readComparative StudyMulticenter Study
PubMed Publisher
In one paragraph

Article in European journal of clinical pharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.1field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 1 country.

Anne Katrine EekRegional Medicines Information & Pharmacovigilance Centre (RELIS), Oslo University Hospital HF Rikshospitalet, PO Box 4950 Nydalen, 0424, Oslo, Norway. ankeek@ous-hf.no.ORCID http://orcid.org/0000-0001-5884-1046
Erik ØieDiakonhjemmet Hospital, Diakonveien 12, 0370, Oslo, Norway.
Anne Gerd GranasSchool of Pharmacy, University of Oslo, PO Box 1072 Blindern, 0316, Oslo, Norway.
Diakonhjemmet Hospital · NOOslo University Hospital · NOUniversity of Oslo · NO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe development of non-vitamin K-dependent oral anticoagulants (NOACs) is a new alternative to treatment with warfarin. The purpose of this study was to explore drug prescription decisions of NOACs or warfarin from hospital physicians in cardiovascular departments.

methodsA qualitative study with focus group interviews was conducted in three different hospitals. The interview guide explored the background of prescribing anticoagulants (warfarin, dabigatran, rivaroxaban, and apixaban) and experiences with effect and side-effects they had observed in patients.

resultsThe systematic text condensation eluded four main themes: when to prescribe NOACs, concern about side-effects, pharmaceutical properties and patient adherence, and prescribing policy and intra-professional communication. All available anticoagulants were prescribed. However, no specific NOAC was preferred. Factors perceived as contraindications for NOACs varied among the doctors. Most had observed side-effects of NOACs; however, these rarely influenced prescribing decisions due to small differences in safety profiles. Few drug-drug interactions and fixed daily doses made NOACs easy to prescribe; but some doctors had experienced lack of drug effect for some patients. Non-adherence with NOACs was harder to spot. Some different prescribing cultures had evolved between the different hospitals and between general practitioners.

conclusionThe hospital physicians chose anticoagulants based on patient conditions as renal function, bleeding risks, and drug interactions being the most common taken into account. They could not say which NOAC was best, and wish that future studies could compare the different NOACs, and not just compare with warfarin.

Indexed as

Practice Patterns, Physicians'Administration, OralAnticoagulantsAntithrombinsCardiovascular DiseasesClinical Decision-MakingDabigatranDrug MonitoringDrug ResistanceFactor Xa InhibitorsFocus GroupsGeneral PractitionersHemorrhageHumansMedical Staff, HospitalMedication AdherenceAnticoagulantsAntithrombinsapixabanDabigatranFactor Xa InhibitorsPyrazolesPyridonesRivaroxabanWarfarinAdverse reactionsAnticoagulantsDrug prescriptionsDrug-related side-effectsHospital physiciansNOACWarfarin

Identifiers

PMID29149366
OpenAlexW2769788597

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.